RECIST 1.1-Update and Clarification: From the RECIST Committee

Overview

Journal Eur J Cancer

Specialty Oncology

Date 2016 May 19

PMID 27189322

Citations 849

Authors

Lawrence H Schwartz

Saskia Litiere

Elisabeth de Vries

Robert Ford

Stephen Gwyther

Sumithra Mandrekar

Lalitha Shankar

Jan Bogaerts

Alice Chen

Janet Dancey

Wendy Hayes

F Stephen Hodi

Otto S Hoekstra

Erich P Huang

Nancy Lin

Yan Liu

Patrick Therasse

Jedd D Wolchok

Lesley Seymour

Affiliations

Soon will be listed here.

Abstract

The Response Evaluation Criteria in Solid Tumours (RECIST) were developed and published in 2000, based on the original World Health Organisation guidelines first published in 1981. In 2009, revisions were made (RECIST 1.1) incorporating major changes, including a reduction in the number of lesions to be assessed, a new measurement method to classify lymph nodes as pathologic or normal, the clarification of the requirement to confirm a complete response or partial response and new methodologies for more appropriate measurement of disease progression. The purpose of this paper was to summarise the questions posed and the clarifications provided as an update to the 2009 publication.

Citing Articles

Integration of intratumoral and peritumoral CT radiomic features with machine learning algorithms for predicting induction therapy response in locally advanced non-small cell lung cancer.

Cai F, Guo Z, Wang G, Luo F, Yang Y, Lv M BMC Cancer. 2025; 25(1):461.

PMID: 40082786 PMC: 11907900. DOI: 10.1186/s12885-025-13804-x.

Efficacy of Conversion Surgery for Initially Unresectable Biliary Tract Cancer That Has Responded to Down-Staging Chemotherapy.

Murakami T, Matsuyama R, Yabushita Y, Homma Y, Sawada Y, Miyake K Cancers (Basel). 2025; 17(5).

PMID: 40075720 PMC: 11898483. DOI: 10.3390/cancers17050873.

Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching.

Zhou Q, Li H, Liang Y, Li R, Wang X, Wang W Radiol Med. 2025; .

PMID: 40072804 DOI: 10.1007/s11547-025-01975-3.

Impact of Induction Chemotherapy Before Radical Chemoradiation in Oral Cavity Squamous Cell Carcinoma: A Tertiary Centre Experience.

Lohani S, Prasai G, Tandon S, Ahlawat P, Antony V, Bellige A Indian J Otolaryngol Head Neck Surg. 2025; 77(2):960-966.

PMID: 40065951 PMC: 11890703. DOI: 10.1007/s12070-024-05315-1.

5-Hydroxymethylcytosine modifications in circulating cell-free DNA: frontiers of cancer detection, monitoring, and prognostic evaluation.

Song D, Zhang Z, Zheng J, Zhang W, Cai J Biomark Res. 2025; 13(1):39.

PMID: 40055844 PMC: 11887266. DOI: 10.1186/s40364-025-00751-9.

References

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Janku F, Berry D, Gong J, Parsons H, Stewart D, Kurzrock R . Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res. 2012; 18(22):6356-63. DOI: 10.1158/1078-0432.CCR-12-0178. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Sullivan D, Schwartz L, Zhao B . The imaging viewpoint: how imaging affects determination of progression-free survival. Clin Cancer Res. 2013; 19(10):2621-8. PMC: 3654392. DOI: 10.1158/1078-0432.CCR-12-2936. View

Miller A, Hoogstraten B, STAQUET M, Winkler A . Reporting results of cancer treatment. Cancer. 1981; 47(1):207-14. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. View